Healthcare Professional Man in suit

Your Partnership Matters in Cancer Research

We are passionate about improving health and are committed to helping people with cancer. Merck Oncology Clinical Trials are investigating different study medications alone, or in combination with other study medications, or standard of care therapy, to see if they can help prevent, find, or treat cancer. We have clinical trials planned in multiple cancer types.

There is a great deal more to understand and learn about which patients are likely to respond to these types of studies. Ongoing research may help us understand this, as well as provide insights regarding how to best test for expression of biomarkers that may better direct clinical care.

To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

91

Trials in 30+ cancer types

Explore Active Clinical Trials

  • expand all
  • |
  • collapse all
Trial Description Trial Number Condition Phase Status
Study of First-line Pembrolizumab With Lenvatinib in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy
7902-011 Urothelial Carcinoma Phase 3 Recruiting
Study of Pembrolizumab in Participants With High Risk Non-muscle Invasive Bladder Cancer
057 Bladder Cancer Phase 2 Recruiting
Efficacy and Safety of Pembrolizumab in Combination With Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer
676 High-risk Non-muscle Invasive Bladder Cancer Phase 3 Recruiting
Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer
866 Urinary Bladder Cancer, Muscle-invasive Phase 3 Recruiting
Perioperative Pembrolizumab Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer
905 Urinary Bladder Cancer, Muscle-invasive Phase 3 Recruiting
A Study of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer
045 Urothelial Cancer Phase 3 Active, not recruiting
Study of Pembrolizumab in Participants With Advanced Urothelial Cancer
052 Urothelial Cancer Phase 2 Active, not recruiting
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma
361 Urothelial Carcinoma Associated 1 RNA, Human Phase 3 Active, not recruiting
Trial Description Trial Number Condition Phase Status
Study of Pembrolizumab or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
412 Head and Neck Neoplasms Phase 3 Active, not recruiting
Study of Pembrolizumab in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma or Locally Advanced Unresectable cSCC
629 Squamous Cell Carcinoma Phase 2 Active, not recruiting
Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma
630 Carcinoma, Squamous Cell Phase 3 Recruiting
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma
689 Head and Neck Neoplasms Phase 3 Recruiting
Pembrolizumab Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer
040 Head and Neck Squamous Cell Cancer Phase 3 Active, not recruiting
A Study of Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
048
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer
Phase 3 Active, not recruiting
Study of MK-3475 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy
055 Head and Neck Squamous Cell Carcinoma Phase 2 Active, not recruiting
Study of Pembrolizumab in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer
122 Nasopharyngeal Neoplasms Phase 3 Active, not recruiting
Trial Description Trial Number Condition Phase Status
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab With or Without Lenvatinib as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer
7902-006 Nonsquamous Non-small Cell Lung Cancer Phase 3 Recruiting
Efficacy and Safety Study of Pembrolizumab With or Without Lenvatinib in Adults With Programmed Cell Death-Ligand 1 -Positive Treatment-naïve Non-small Cell Lung Cancer
7902-007 Non-small Cell Lung Cancer Phase 3 Recruiting
Efficacy and Safety of Pembrolizumab With Lenvatinib vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer and Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy
7902-008 Metastatic Non-Small Cell Lung Cancer Phase 3 Recruiting
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line Metastatic Nonsquamous Non-Small-Cell Lung Cancer
KEYLYNK-006 Carcinoma, Non-squamous Non-small-cell Lung Phase 3 Recruiting
A Study of Pembrolizumab With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer
KEYLYNK-008 Carcinoma, Squamous Cell, Non-small-cell Lung Phase 3 Recruiting
Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy
091 Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer
598 Carcinoma, Non-Small-Cell Lung Phase 3 Active, not recruiting
Efficacy and Safety of Pembrolizumab With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer
671 Early-stage Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI) -Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
789 Non-small Cell Lung Cancer Phase 3 Recruiting
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.
799 Non-small Cell Lung Cancer Phase 2 Recruiting
Efficacy and Safety Study of Stereotactic Body Radiotherapy With or Without Pembrolizumab in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer
867 Non-Small Cell Lung Cancer Phase 3 Recruiting
Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer
010 Non Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3 Active, not recruiting
Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer
011
  • Solid Tumor
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
Phase 1 Active, not recruiting
A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer
021 Non-small Cell Lung Carcinoma Phase 1/Phase 2 Active, not recruiting
Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer
024 Non-Small Cell Lung Carcinoma Phase 3 Active, not recruiting
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab in Chinese Participants With Non-Small-Cell Lung Cancer
032 Non-Small-Cell Lung Cancer Phase 1 Active, not recruiting
Study of Pembrolizumab Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 -Positive Advanced or Metastatic Non-Small Cell Lung Cancer
042 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer
189 Non-Small-Cell Lung Carcinoma Phase 3 Active, not recruiting
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer
407 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
A Study of Pembrolizumab in Combination With Etoposide/Platinum for Participants With Extensive Stage Small Cell Lung Cancer
604
  • Small Cell Lung Cancer
  • SCLC
Phase 3 Active, not recruiting
Trial Description Trial Number Condition Phase Status
Safety and Efficacy Study of Pembrolizumab Combined With Lenvatinib as First-line Intervention in Adults With Advance Melanoma
7902-003 Malignant Melanoma Phase 3 Recruiting
Efficacy and Safety of Lenvatinib Plus Pembrolizumab for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 -Exposed Participants
7902-004 Advanced Melanoma Phase 2 Active, not recruiting
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma
716 Melanoma Phase 3 Recruiting
Study to Evaluate the Safety and Efficacy of Pembrolizumab as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma
913 Merkel Cell Carcinoma Phase 3 Recruiting
A Study of the Safety and Efficacy of Pembrolizumab in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma
022
  • Melanoma
  • Solid Tumors
Phase 1/Phase 2 Active, not recruiting
Safety and Tolerability of Pembrolizumab + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma
029
  • Renal Cell Carcinoma
  • Melanoma
Phase 1/Phase 2 Active, not recruiting
Study of Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma
054 Melanoma Phase 3 Active, not recruiting
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma
942 Melanoma Phase 2 Recruiting
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab Compared to Ipilimumab in Participants With Advanced Melanoma
006 Melanoma Phase 3 Completed